Urologic Oncology: Biomarkers and Targeted Therapies
A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Disease Biomarker".
Deadline for manuscript submissions: 31 October 2024 | Viewed by 408
Special Issue Editor
2. Department of Urology, Clinical Emergency County Hospital, 300723 Timișoara, Romania
Interests: urological oncology; functional urology; urodynamics; sexual medicine
Special Issue Information
Dear Colleagues,
Urological malignancies, including prostate, urothelial, renal, and testicular cancers, pose significant challenges to patients due to their heterogeneity and variable responses to treatment. While traditional approaches can lead to suboptimal outcomes and unnecessary toxicity, new targeted therapies may represent a paradigm shift, offering personalised strategies tailored to the unique molecular profiles of tumors and patients.
This Special Issue aims to bring together the latest advances in the discovery, validation, and clinical application of prognostic approaches and monitoring biomarkers for uro-oncology targeted therapies. From genomic and proteomic signatures (taking advantage of recent advances in machine learning and artificial intelligence) to circulating tumor cells and imaging biomarkers, each contribution will provide new insights into treatment response prediction, prognosis estimation, and therapy resistance mechanisms.
We encourage the submission of original research articles and comprehensive literature reviews that provide an overview of the interdisciplinary collaboration between basic scientists and clinicians and accelerate the translation of biomarker discoveries from bench to bedside, ultimately improving patient outcomes and survival.
Dr. Razvan Bardan
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- targeted therapy
- urological oncology
- biomarker
- epigenetic changes
- tumor mutational burden
- proteomics
- circulating tumor cells
- liquid biopsy
- radiomics
